Kleptomania
Return to Library
|
Free Kleptomania Articles |
|
|
|
|
New data from University of Minnesota, Medical Department illuminate research in kleptomania
2009 MAY 18 - (NewsRx.com) -- "Kleptomania is a rare psychiatric disorder characterized by recurrent stealing and for which there exists no empirically validated treatments. This study examined the efficacy and tolerability of the opioid antagonist naltrexone in adults with kleptomania who have urges to steal," investigators in the United States report. "An 8-week, double-blind, placebo-controlled trial was conducted to evaluate the safety and efficacy of oral naltrexone for kleptomania. Twenty-five individuals with DSM-IV kleptomania were randomized to naltrexone (dosing ranging from 50 mg/day to 150 mg/day) or placebo. Twenty-three subjects (92%) completed the study. Subjects were assessed every 2 weeks with the Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (K-YBOCS), the urge and behavior subscales of the K-YBOCS, the Kleptomania Symptom Assessment Scale (K-SAS), the Clinical Global Impressions Scale (CGI), and measures of depression, anxiety, and psychosocial functioning. Subjects assigned to naltrexone had significantly greater reductions in K-YBOCS total scores (p = .001), stealing urges (p = .032), and stealing behavior (p < .001) compared with subjects on placebo. Subjects assigned to naltrexone also had greater improvement in overall kleptomania severity (reflected in the CGI scores) (p < .001). The mean effective dose of naltrexone was 116.7 (44.4) mg/day. Naltrexone demonstrated statistically significant reductions in stealing urges and behavior in kleptomania," wrote J.E. Grant and colleagues, University of Minnesota, Medical Department. The researchers concluded: "Naltrexone was well tolerated." Grant and colleagues published their study in Biological Psychiatry (A Double-Blind, Placebo-Controlled Study of the Opiate Antagonist, Naltrexone, in the Treatment of Kleptomania. Biological Psychiatry, 2009;65(7):600-606). For additional information, contact J.E. Grant, University of Minnesota, School Medical, Dept. of Psychiatry, 2450 Riverside Avenue, Minneapolis, MN 55454, USA. The publisher of the journal Biological Psychiatry can be contacted at: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA. Keywords: United States, Minneapolis, Alcohol Antagonist, Anticraving, Anxiety Disorder, Clinical Trial Research, Depressant, Drugs, Impulse Control Disorder, Kleptomania, Mental Health, Naltrexone, Obsessive-Compulsive Disorder, Opiate Antagonist, Pharmaceuticals, Pharmacotherapy, Psychiatric, Psychiatry, Therapy, Treatment, University of Minnesota, Medical Department. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
